Dr Reddy's to sell Neurology branded products to Usher-Smith

Under the agreement, Dr Reddy's will receive $70 million as upfront consideration, $40.50 million in near-term milestones and additional financial considerations including, existing contractual obligation and inventory. It will also get sales-based royalties on a quarterly basis.

"Dr. Reddy's would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRA™ (sumatriptan nasal spray) 10 mg, (formerly referred to as "DFN-02"), which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC", the company said in a BSE filing.

The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act, according to the exchange notification.

At 11.22 am, shares of Dr Reddy's Lab traded at ₹2529.65 on BSE, down 2.18% from previous close, while India's benchmark equity index Sensex was down 0.48% at 39,559.98.